Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Moupali Das

Showing results (1-10 of 61) with videos related to

Pageof 7
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 24, 2011
Linkage and retention in HIV care among men who have sex with men in the United StatesKaterina A Christopoulos, Moupali Das, Grant N Colfax
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 5, 2011
The effect of expanded antiretroviral treatment strategies on the HIV epidemic among men who have sex with men in San FranciscoEdwin D Charlebois, Moupali Das, Travis C Porco, et al.
Antiviral Therapy|January 12, 2017
Infrequent development of drug resistance in HIV-1-infected treatment-naive subjects after 96 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide or elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarateNicolas Margot, Stephanie Cox, Moupali Das, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|April 9, 2018
Rare emergence of drug resistance in HIV-1 treatment-naïve patients receiving elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide for 144 weeksNicolas Margot, Stephanie Cox, Moupali Das, et al.
Antiviral Therapy|January 15, 2020
Confirmation of the drug-drug interaction potential between cobicistat-boosted antiretroviral regimens and hormonal contraceptivesSophia R Majeed, Steve West, Kah Hiing Ling, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|April 13, 2018
Pharmacokinetics of Tenofovir Alafenamide When Coadministered With Other HIV AntiretroviralsRebecca Begley, Moupali Das, Lijie Zhong, et al.
Journal of the International AIDS Society|December 21, 2019
Estimation of new HIV diagnosis rates among high-risk, PrEP-eligible individuals using HIV surveillance data at the Metropolitan Statistical Area level in the United StatesRobertino Mera, Susan Scheer, Christoph Carter, et al.
Journal of Urban Health : Bulletin of the New York Academy of Medicine|December 29, 2007
Tripling of methamphetamine/amphetamine use among homeless and marginally housed persons, 1996-2003Moupali Das-Douglas, Grant Colfax, Andrew R Moss, et al.
The Journal of Antimicrobial Chemotherapy|November 17, 2020
Two-dose emtricitabine/tenofovir alafenamide plus bictegravir prophylaxis protects macaques against SHIV infectionElena Bekerman, Stephanie Cox, Darius Babusis, et al.
International Journal of STD & AIDS|March 23, 2016
Correlates of recent HIV testing among substance-using men who have sex with menChristopher Rowe, Tim Matheson, Moupali Das, et al.
Pageof 7

Showing results (1-10 of 61) with videos related to

Sort By:
Pageof 7
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 24, 2011
Linkage and retention in HIV care among men who have sex with men in the United StatesKaterina A Christopoulos, Moupali Das, Grant N Colfax
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 5, 2011
The effect of expanded antiretroviral treatment strategies on the HIV epidemic among men who have sex with men in San FranciscoEdwin D Charlebois, Moupali Das, Travis C Porco, et al.
Antiviral Therapy|January 12, 2017
Infrequent development of drug resistance in HIV-1-infected treatment-naive subjects after 96 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide or elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarateNicolas Margot, Stephanie Cox, Moupali Das, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|April 9, 2018
Rare emergence of drug resistance in HIV-1 treatment-naïve patients receiving elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide for 144 weeksNicolas Margot, Stephanie Cox, Moupali Das, et al.
Antiviral Therapy|January 15, 2020
Confirmation of the drug-drug interaction potential between cobicistat-boosted antiretroviral regimens and hormonal contraceptivesSophia R Majeed, Steve West, Kah Hiing Ling, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|April 13, 2018
Pharmacokinetics of Tenofovir Alafenamide When Coadministered With Other HIV AntiretroviralsRebecca Begley, Moupali Das, Lijie Zhong, et al.
Journal of the International AIDS Society|December 21, 2019
Estimation of new HIV diagnosis rates among high-risk, PrEP-eligible individuals using HIV surveillance data at the Metropolitan Statistical Area level in the United StatesRobertino Mera, Susan Scheer, Christoph Carter, et al.
Journal of Urban Health : Bulletin of the New York Academy of Medicine|December 29, 2007
Tripling of methamphetamine/amphetamine use among homeless and marginally housed persons, 1996-2003Moupali Das-Douglas, Grant Colfax, Andrew R Moss, et al.
The Journal of Antimicrobial Chemotherapy|November 17, 2020
Two-dose emtricitabine/tenofovir alafenamide plus bictegravir prophylaxis protects macaques against SHIV infectionElena Bekerman, Stephanie Cox, Darius Babusis, et al.
International Journal of STD & AIDS|March 23, 2016
Correlates of recent HIV testing among substance-using men who have sex with menChristopher Rowe, Tim Matheson, Moupali Das, et al.
Pageof 7